Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Bridge Investment Group’s Acquisition of Newbury Partners
Latham & Watkins LLP and Kirkland & Ellis LLP acted as legal advisors to Bridge on this transaction. Berkshire Global Advisors served as financial advisor and...
CG Oncology’s $120 Million Series E Financing Round
Latham & Watkins LLP represented CG Oncology in the transaction. CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic...
Alphatec Spine’s $50 Million Revolving Credit Facility
Latham & Watkins represented Alphatec in the transaction. Alphatec Holdings, Inc. (Alphatec) announced the close of an asset-based revolving credit facility in the maximum aggregate amount...
L3Harris Technologies’ $1.96 Billion Acquisition of Link 16 Tactical Data Links Business From Viasat
Latham & Watkins represented Viasat in the transaction while Morrison Foerster served as government contracts and regulatory counsel to L3Harris on regulatory matters. Viasat Inc. (NASDAQ: VSAT),...
Extra Space Storage’s $590 Million Acquisition of Storage Express
Latham & Watkins represented Extra Space in the transaction. Extra Space Storage Inc. and its subsidiaries (collectively Extra Space or the Company) (NYSE: EXR) has completed...
Bitcoin Depot’s Combination With GSR II Meteora Acquisition Corp.
Kirkland & Ellis counseled Lux Vending LLC dba Bitcoin Depot® on the deal, while Latham & Watkins advised GSRM. Lux Vending LLC dba Bitcoin Depot®, a...
Amgen’s $3.7 Billion Acquisition of ChemoCentryx
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
Parsons’ Acquisition of Xator Corporation
Latham & Watkins represented Parsons Corporation in the transaction. Parsons Corporation (NYSE:PSN) has announced that it entered into a definitive agreement to acquire Xator Corporation in...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Avient Corporation’s EUR 1.44 Billion Acquisition of Royal DSM’s Protective Materials Business
Clifford Chance has advised Royal DSM on the deal while Jones Day represented Avient Corporation. Royal DSM, a global purpose-led science-based company, agreed to sell its...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...